Chronic obstructive pulmonary disease is a multifactorial disease characterized by gene-gene interaction as well as environmental effects. The incidence of type 2 diabetes mellitus is proved to be higher in the presence of chronic obstructive pulmonary disease than in the case of its absence. We aimed to study the genotypes of MDR1 (C3435T) gene polymorphism and its relationship with clinical, instrumental, and laboratory parameters in chronic obstructive pulmonary disease associated with type 2 diabetes mellitus. All the patients were divided into two groups. The first group included 53 patients with chronic obstructive pulmonary disease, and the second group included 49 patients with chronic obstructive pulmonary disease with comorbid type 2 diabetes mellitus. The COPD assessment test (CAT), 6-minute walk test, BODE integral index, spirometry, and bioimpedansometry were used for examination. Lipid spectrum, carbohydrate metabolism, endothelial functional status, leptin, adiponectin, and serum levels were also determined by means of enzyme immunoassay. Our study results showed no significant difference between the genotypes of the control group of healthy individuals and patients with chronic obstructive pulmonary disease and comorbid type 2 diabetes mellitus. Though, a certain association of this gene polymorphism with clinical findings by CAT-test, specific parameters of carbohydrate (fasting glucose) and lipid metabolism (total cholesterol and low-density cholesterol lipoproteins), endothelial functional state (nitrate/nitrite level) with the minor allele T available was found.
Le niveau de la ghréline et les types d'habitude alimentaire lors de la combinaison du syndrome de l'intestin irritable, de l'hypertension artérielle et de l'obésité Contexte. La ghréline régule la motilité du tractus gastro-intestinal, la nature du comportement alimentaire, a un effet cardioprotecteur, augmente la vasodilatation et régule la tension artérielle. Objectif. Etudier le niveau de la ghréline basale et postprandiale chez les patients présentant une combinaison de l'hypertension, le syndrome du côlon irritable sur le fond de l'obésité et du comportement alimentaire. Méthodes. L'étude a porté sur 24 patients avec syndrome du côlon irritable, constipation, poids normal, 18 patients avec de l'hypertension de 2-ème degré sur le fond de l'obésité et 54 patients souffrant de troubles concomitants (syndrome du côlon irritable avec constipation sur le fond de l'hypertension et l'obésité I-III).
The effectiveness of pulmonary rehabilitation (PR) has not yet been established in patients with asthma – chronic obstructive pulmonary disease overlap (ACO) depending on their nutritional status. We aimed to evaluate the effectiveness of a short-term PR program in patients with comorbid asthma, chronic obstructive pulmonary disease (COPD), and obesity. We included 40 ACO patients and divided them into 3 groups according to body mass index (BMI) and then subdivided them into PR (n=21) and control (n=19) groups. The COPD Assessment Test (CAT), the Asthma Control Test (ACT), and the modified Medical Research Council dyspnea scale (mMRS) were used to evaluate symptoms levels. BODE index (body mass index, forced expiratory volume in one second, dyspnoea, and 6-min walk distance) was used to evaluate the effectiveness of pulmonary rehabilitation. In addition, spirometry and bioimpedansometry were performed. All measurements were done before and after a 6-month PR program. A significantly lower decline in the BODE index was observed in overweight patients (decreased by 43.6% compared to baseline and lower by 40.7% compared to the control group). The six-minute walking test (6MWT) significantly increased in all groups (p<0.001). There was a decrease in total CAT score by 25.4% and by 31.2% in the overweight group (p<0.001). The BMI decreased more in the obese group (by 9.4% compared to baseline). Our study result showed that early use of PR program significantly improves functional capacity and BODE index, leads to dyspnea and CAT scores reduction and improvement in pulmonary function, cause a decrease in BMI, body fat percentage, and visceral fat level, and an increase in muscle mass in overweight and obese patients with ACO.
Introduction. The problem of pathology of internal organs comorbidity with obesity has become particularly relevant in recent years. The association of obesity with gastrointestinal pathology, in particular, irritable bowel syndrome has not been studied enough. The role of melatonin in the development of these diseases and the possibility of using its synthetic forms in their treatment has drawn the attention of researchers in recent years. Objective-to study the effect of synthetic melatonin on blood pressure, autonomic status, sleep quality, the level of ghrelin and serotonin in patients suffering from obesity combined with arterial hypertension and irritable bowel syndrome with constipation. Material and methods. The study involved 78 patients, of which 34 were diagnosed with irritable bowel syndrome with constipation combined with obesity, and 54 of those who suffered obesity, irritable bowel syndrome combined with arterial hypertension. Patients of each group were divided into two subgroups depending on the treatment complex, one of which received standard therapy, and in the case of combination with arterial hypertension, they also received three component antihypertensive therapy, while the other two received synthetic melatonin before the standard therapy. Results. There was a more significant decrease in average daily systolic and diastolic blood pressure values under the influence of therapy with the inclusion of vitae-melatonin and a significant decrease in the number of patients with a non-dipper and night-picker blood pressure profile. The more positive influence of comprehensive therapy with the inclusion of melatonin on parameters of heart rate variability and its quality was noted. The administration of melatonin combined with a standard therapy led to an increase in the frequency of the bowel movement, approaching serotonin in the serum to normal rates and a decrease in the postprandial level of ghrelin without changes in its fasting concentration. Conclusions. The obtained results are indicative of the positive effect of melatonin on obesity combined with irritable bowel syndrome with constipation and arterial hypertension.
Investigation of the mechanisms promoting the development of irritable bowel syndrome (IBS) in obese patients is one of the most important issues of modern medicine. We examined 97 patients suffering from IBS. The group of comparison included 10 individuals with obesity. The control group included 21 practically healthy individuals. The levels of C-reactive protein (CRP) in the blood serum, tumor necrosis factor-α (TFNα), transforming growth factor-β1 (TGFβ1), interleukin-10 (IL-10), 8-isoprostane (IP), ceruloplasmin (CP) were examined. Endotoxicosis intensity was identified by the content of average molecular peptides in the blood and the Limulus Amebocyte Lysate (LAL) test. In the case of IBS with prevailing diarrhea, especially its comorbid course with obesity, cytokine imbalance was observed, which was manifested by a decreased amount of IL-10 in the blood serum and increased levels of TNFα and TGFβ1. Patients suffering from irritable bowel syndrome with prevailing diarrhea associated with obesity were characterized by high levels of C-reactive protein, fibrinogen and average molecules, increased content of pro-inflammatory cytokines (TFNα and TGFβ1) with a decreased content of IL-10, as well as imbalance of the pro-oxidant and anti-oxidant blood systems (increased content of 8-isoprostane and ceruloplasmin).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.